These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 28644771)

  • 21. MET alterations in biphasic squamoid alveolar papillary renal cell carcinomas and clinicopathological features.
    Denize T; Just PA; Sibony M; Blons H; Timsit MO; Drossart T; Jakubowicz D; Broudin C; Morini A; Molina T; Vano Y; Auvray-Kuentz M; Richard S; Mejean A; Gimenez Roqueplo AP; Burnichon N; Verkarre V
    Mod Pathol; 2021 Mar; 34(3):647-659. PubMed ID: 32770124
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial.
    Negrier S; Rioux-Leclercq N; Ferlay C; Gross-Goupil M; Gravis G; Geoffrois L; Chevreau C; Boyle H; Rolland F; Blanc E; Ravaud A; Dermeche S; Flechon A; Albiges L; Pérol D; Escudier B;
    Eur J Cancer; 2020 Apr; 129():107-116. PubMed ID: 32146304
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of HSP 90 is associated with potent anti-tumor activity in Papillary Renal Cell Carcinoma.
    Pahwa R; Dubhashi J; Singh A; Jailwala P; Lobanov A; Thomas CJ; Ceribelli M; Wilson K; Ricketts CJ; Vocke CD; Wells C; Bottaro DP; Linehan WM; Neckers L; Srinivasan R
    J Exp Clin Cancer Res; 2022 Jun; 41(1):208. PubMed ID: 35754026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation.
    Henry RE; Barry ER; Castriotta L; Ladd B; Markovets A; Beran G; Ren Y; Zhou F; Adam A; Zinda M; Reimer C; Qing W; Su W; Clark E; D'Cruz CM; Schuller AG
    Oncotarget; 2016 Sep; 7(36):57651-57670. PubMed ID: 27472392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A pharmacokinetic-pharmacodynamic model for the MET tyrosine kinase inhibitor, savolitinib, to explore target inhibition requirements for anti-tumour activity.
    Jones RDO; Grondine M; Borodovsky A; San Martin M; DuPont M; D'Cruz C; Schuller A; Henry R; Barry E; Castriotta L; Anjum R; Petersson K; Sahota T; Ahmed GF
    Br J Pharmacol; 2021 Feb; 178(3):600-613. PubMed ID: 33125717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Papillary renal cell carcinoma: A review of the current therapeutic landscape.
    Courthod G; Tucci M; Di Maio M; Scagliotti GV
    Crit Rev Oncol Hematol; 2015 Oct; 96(1):100-12. PubMed ID: 26052049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array.
    Albiges L; Guegan J; Le Formal A; Verkarre V; Rioux-Leclercq N; Sibony M; Bernhard JC; Camparo P; Merabet Z; Molinie V; Allory Y; Orear C; Couvé S; Gad S; Patard JJ; Escudier B
    Clin Cancer Res; 2014 Jul; 20(13):3411-21. PubMed ID: 24658158
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317.
    Gordon MS; Hussey M; Nagle RB; Lara PN; Mack PC; Dutcher J; Samlowski W; Clark JI; Quinn DI; Pan CX; Crawford D
    J Clin Oncol; 2009 Dec; 27(34):5788-93. PubMed ID: 19884559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The molecular characterization and therapeutic strategies of papillary renal cell carcinoma.
    Chen Q; Cheng L; Li Q
    Expert Rev Anticancer Ther; 2019 Feb; 19(2):169-175. PubMed ID: 30474436
    [No Abstract]   [Full Text] [Related]  

  • 30. Relationships between Chromosome 7 Gain, MET Gene Copy Number Increase and MET Protein Overexpression in Chinese Papillary Renal Cell Carcinoma Patients.
    Yin X; Zhang T; Su X; Ji Y; Ye P; Fu H; Fan S; Shen Y; Gavine PR; Gu Y
    PLoS One; 2015; 10(12):e0143468. PubMed ID: 26636767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review.
    Rochigneux P; Thomassin-Piana J; Laibe S; Brunelle S; Salem N; Escudier B; Vassal G; Gravis G
    BMC Cancer; 2018 Nov; 18(1):1159. PubMed ID: 30466410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.
    Oxnard GR; Yang JC; Yu H; Kim SW; Saka H; Horn L; Goto K; Ohe Y; Mann H; Thress KS; Frigault MM; Vishwanathan K; Ghiorghiu D; Ramalingam SS; Ahn MJ
    Ann Oncol; 2020 Apr; 31(4):507-516. PubMed ID: 32139298
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Re: Toni K. Choueiri, Daniel Y.C. Heng, Jae Lyun Lee, et al. Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial. JAMA Oncol. In press. https://doi.org/10.1001/jamaoncol.2020.2218: SAVOIR: From Own Goal to Winning Goal?
    Mollica V; Rizzo A; Massari F
    Eur Urol Oncol; 2020 Aug; 3(4):561-562. PubMed ID: 32653414
    [No Abstract]   [Full Text] [Related]  

  • 34. Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma.
    Tripathi A; Tangen CM; Plets M; Li X; Tretiakova M; Humphrey PA; Adeniran A; Barata PC; Gulati S; Bergerot CD; Pruthi DK; Thompson IM; Lara PN; Lerner SP; Pal SK; Shuch BM
    BJU Int; 2024 Oct; 134(4):596-601. PubMed ID: 39014969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Three-dimensional coculture provides an improved in vitro model for papillary renal cell carcinoma.
    Rosette KA; Lander SM; VanOpstall C; Looyenga BD
    Am J Physiol Renal Physiol; 2021 Jul; 321(1):F33-F46. PubMed ID: 34029144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Savolitinib: First Approval.
    Markham A
    Drugs; 2021 Sep; 81(14):1665-1670. PubMed ID: 34455538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Capmatinib in
    Wolf J; Seto T; Han JY; Reguart N; Garon EB; Groen HJM; Tan DSW; Hida T; de Jonge M; Orlov SV; Smit EF; Souquet PJ; Vansteenkiste J; Hochmair M; Felip E; Nishio M; Thomas M; Ohashi K; Toyozawa R; Overbeck TR; de Marinis F; Kim TM; Laack E; Robeva A; Le Mouhaer S; Waldron-Lynch M; Sankaran B; Balbin OA; Cui X; Giovannini M; Akimov M; Heist RS;
    N Engl J Med; 2020 Sep; 383(10):944-957. PubMed ID: 32877583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Parent and Metabolite Concentration-QT Modeling to Evaluate QT-Interval Prolongation at Savolitinib Therapeutic Doses.
    Schalkwijk S; Sahota T; Verheijen RB; Harmer AR; Ahmed GF
    AAPS J; 2021 Mar; 23(3):46. PubMed ID: 33733338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Papillary renal cell carcinoma with a somatic mutation in MET in a patient with autosomal dominant polycystic kidney disease.
    Zhang W; Tan AY; Blumenfeld J; Liu G; Michaeel A; Zhang T; Robinson BD; Salvatore SP; Kapur S; Donahue S; Bobb WO; Rennert H
    Cancer Genet; 2016; 209(1-2):11-20. PubMed ID: 26718059
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In silico DNA methylation analysis identifies potential prognostic biomarkers in type 2 papillary renal cell carcinoma.
    Yang M; Hlady RA; Zhou D; Ho TH; Robertson KD
    Cancer Med; 2019 Sep; 8(12):5760-5768. PubMed ID: 31361072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.